NewEdge Advisors LLC Has $33.69 Million Stock Holdings in Amgen Inc. $AMGN

NewEdge Advisors LLC decreased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 3.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 93,040 shares of the medical research company’s stock after selling 2,899 shares during the period. NewEdge Advisors LLC’s holdings in Amgen were worth $33,691,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of AMGN. Rational Advisors Inc. lifted its position in Amgen by 13.7% during the second quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock worth $72,000 after acquiring an additional 24 shares during the last quarter. Beacon Financial Advisory LLC increased its stake in shares of Amgen by 2.0% during the second quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock worth $461,000 after purchasing an additional 25 shares during the period. Legacy Financial Advisors Inc. increased its stake in shares of Amgen by 0.8% during the second quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock worth $1,234,000 after purchasing an additional 26 shares during the period. Roman Butler Fullerton & Co. lifted its holdings in Amgen by 1.4% during the 2nd quarter. Roman Butler Fullerton & Co. now owns 1,956 shares of the medical research company’s stock worth $705,000 after purchasing an additional 27 shares during the last quarter. Finally, High Note Wealth LLC lifted its holdings in Amgen by 5.8% during the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock worth $166,000 after purchasing an additional 28 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen and AstraZeneca reported that the Phase 3 DeLLphi-305 trial met its primary endpoint. Imdelltra combined with Imfinzi significantly improved overall survival in first-line extensive-stage small-cell lung cancer and also met progression-free survival and response-rate endpoints, strengthening the commercial outlook for Imdelltra. Amgen Imdelltra Phase 3 results
• Positive Sentiment: William Blair maintained a Buy rating, citing the Imdelltra Phase 3 success as support for Amgen’s pipeline and investment case. Piper Sandler also reaffirmed its Buy rating. Imdelltra analyst rating
• Neutral Sentiment: Amgen is scheduled to present at the Morgan Stanley Global Healthcare Conference, potentially providing updates on olpasiran, Imdelltra and broader pipeline priorities. Amgen Morgan Stanley conference presentation
• Neutral Sentiment: Analyst views remain mixed: Wells Fargo reiterated Hold, while Cantor Fitzgerald maintained Neutral with a $400 price target, suggesting limited near-term upside from recent levels. Wells Fargo Amgen rating
• Negative Sentiment: Novartis’ Phase 3 pelacarsen trial failed to reduce cardiovascular events despite lowering Lp(a), raising doubts about whether the biomarker translates into clinical benefits. Investors consequently questioned the prospects for Amgen’s olpasiran, which remains in a large late-stage heart-outcomes study. Novartis cholesterol drug setback
• Negative Sentiment: BMO downgraded Amgen to Market Perform from Outperform, citing a less favorable risk-reward balance and limited near-term upside. Broader market pressure from higher oil prices, inflation concerns and interest-rate uncertainty has added to selling pressure. BMO Amgen downgrade

Analyst Ratings Changes

A number of brokerages have commented on AMGN. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Mizuho lifted their target price on Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a report on Tuesday, August 18th. Robert W. Baird boosted their target price on shares of Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. Wells Fargo & Company upped their price target on shares of Amgen from $400.00 to $435.00 and gave the company an “equal weight” rating in a research note on Friday, September 4th. Finally, Oppenheimer raised their price target on shares of Amgen from $400.00 to $450.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $381.68.

Amgen Trading Down 0.5%

Shares of NASDAQ:AMGN opened at $391.27 on Thursday. The business’s 50 day simple moving average is $400.14 and its 200 day simple moving average is $367.79. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $447.03. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The company has a market capitalization of $211.53 billion, a P/E ratio of 24.32, a P/E/G ratio of 2.83 and a beta of 0.43.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, research analysts anticipate that Amgen Inc. will post 22.97 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s payout ratio is 62.65%.

Insider Transactions at Amgen

In other Amgen news, SVP Rachna Khosla sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,642,098.28. This trade represents a 23.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is owned by insiders.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and rare diseases. The company uses biologic research, genetics and other advanced technologies to develop treatments intended to address significant unmet medical needs.

Amgen’s medicines include Enbrel for certain inflammatory diseases; Prolia and Evenity for bone-related conditions; Xgeva for complications associated with cancer and bone disease; Repatha for cardiovascular risk reduction; Otezla for inflammatory conditions; and Aimovig for migraine prevention.